Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 9

Results For "iNGEN"

170 News Found

USFDA approves Roche’s Columvi for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma
Drug Approval | June 19, 2023

USFDA approves Roche’s Columvi for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma

Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma


Novartis to acquire Chinook Therapeutics for US$ 3.2 bn
News | June 12, 2023

Novartis to acquire Chinook Therapeutics for US$ 3.2 bn

Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease


Venus Remedies receives Ukrainian GMP approval for Its Carbapenem, Oncology parenteral facilities
News | June 08, 2023

Venus Remedies receives Ukrainian GMP approval for Its Carbapenem, Oncology parenteral facilities

The company expects this approval in Baddi to pave the way for GMP certifications from European Medicines Agency and other PIC/S member nations


Brinton appoints Amit Jain as President & Head of Domestic Business
People | June 07, 2023

Brinton appoints Amit Jain as President & Head of Domestic Business

Jain will have oversight of Brinton's domestic operations, including business development, sales, and marketing


Lonza launches TheraPEAK T-VIVO cell culture medium to accelerate cell therapy development
News | May 24, 2023

Lonza launches TheraPEAK T-VIVO cell culture medium to accelerate cell therapy development

Lonza launches the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation developed to optimize and streamline CAR T-cell manufacturing


Biocon approves NCD issue
News | April 27, 2023

Biocon approves NCD issue

The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.


Venus Remedies secures marketing authorization from UK MHRA for Cisplatin
News | April 27, 2023

Venus Remedies secures marketing authorization from UK MHRA for Cisplatin

Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country


Siegfried breaks ground on new R&D center for drug substances in Switzerland
News | April 26, 2023

Siegfried breaks ground on new R&D center for drug substances in Switzerland

The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth